AcelRX Pharmaceuticals, Inc. Securities Fraud Investigation
Shamis Gentile, a corporate securities fraud law firm, announces the investigation of a class action lawsuit on behalf of purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 9, 2021.
If you purchased AcelRx securities between March 17, 2020 and February 12, 2021 and would like to join the action, please click “Join This Class Action,” above.
Press Release
SHAMIS GENTILE, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadlines – ACRX
WHY: New York, N.Y., June 9, 2021. Shamis Gentile, a corporate securities fraud law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 9, 2021.
WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the AcelRx class action, please call Andrew J. Shamis, Esq. at 305-479-2299 or email info@shamisgentile.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 9, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY SHAMIS GENTILE LAW: Shamis & Gentile, P.A. is dedicated in helping misled shareholders recover damages caused by corporate fraud and other misconduct. Our securities attorneys have a wealth of knowledge and experience handling complex litigation cases and achieving significant victories and settlements for clients (over 500 million recovered and counting). In addition to our experience litigating securities cases, our attorneys have been routinely certified class counsel throughout the country where our firm has gained a reputation of one that litigates the right way and achieves large monetary settlements. Our team comes from diverse and unique backgrounds, making us equipped to bring the fight anytime and anywhere on behalf of our clients.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA (the Company’s lead product candidate, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to severe acute pain); (2) as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays; (3) the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the AcelRx class action, contact us at info@shamisgentile.com for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Andrew J. Shamis, Esq.
Shamis & Gentile, P.A.
Miami Headquarters
14 NE 1st Ave, Suite 705,
Miami, FL 33132
Tel: 305-479-2299
Fax: 786-623-0915
